Study results:
1. Absorption of amorphous calcium carbonate in the intestine is 2-folds higher than that of crystalline calcium carbonate — when the calcium is taken after a meal.
2. A single case showed that when taken on an empty stomach, amorphous calcium carbonate absorption in the intestine was 4.6-folds higher than crystalline calcium carbonate.
Amorphous calcium carbonate (ACC) demonstrated:
1. 50% reduction in bone loss vs. Caltrate (Pfizer) and Calcium-Citrate (GNC)
2. 34% increase in bone formation induction vs. Caltrate (Pfizer) and Calcium-Citrate (GNC).
3. 37% increase in mechanical strength vs. Caltrate (Pfizer) and Calcium-Citrate (GNC).
Absorption of amorphous calcium carbonate is better than that of crystalline calcium carbonate.
• 40% increase in gastrointestinal calcium absorption
• 30% increase in bone calcium absorption
• 27% increase in bone calcium retention
Amorphical consistently continues to explore the therapeutic advantages of the Gastrolith, in order to provide innovative medicine from nature for treating metabolic bone diseases.
Amorphical is currently conducting a number of clinical studies aimed to test the efficacy of amorphous calcium carbonate in several indications. Additional studies are being designed and are expected to be launched in the near future.
We believe that the advantages of our unique amorphous calcium carbonate products will contribute greatly to the well-being of millions of people worldwide.
Content on this site is not considered advice, a recommendation or medical opinion and does not replace consultation with a doctor
Amorphical: Harash St. 11, Nes-Ziona, Israel
Office: 08-6995333
Информация, содержащаяся на этом сайте не является советом, рекомендацией или медицинским мнением и не заменяет консультацию с врачом Аморфикаль: Harash St. 11, Nes-Ziona, Israel Офис: 08-6995333
.jpg)
